Can you take oxytocin while breastfeeding?

How much oxytocin gets into breastmilk

Maternal Levels. Sixty-two nursing mothers who were 3 to 9 months postpartum, 26 with probable postnatal depression and 36 unlikely to have postnatal depression, had oxytocin measured in breastmilk at baseline and after administration of 12 IU (26.9 mcg) of intranasal oxytocin spray (Syntocinon) or placebo into each nostril in a randomized, double-blind fashion. Milk samples of 5 mL were collected during nursing and 30 to 45 minutes after administration of the nasal spray. Mothers with postnatal depression had baseline oxytocin milk levels of 227 picograms/5 mL and those without had an average of 209 picogram/5 mL, but the difference was not statistically significant. After the placebo nasal spray, there was no change in milk oxytocin levels in either group. After receiving the oxytocin nasal spray, milk oxytocin levels averaged about 700 picogram/5 mL in the non-depression group, but only about 300 picogram/5 mL in the postnatal depression group.

Infant Levels. Relevant published information was not found as of the revision date.

What has been seen in breastfed infants

Relevant published information was not found as of the revision date.

Effects on milk supply

Nasal spray. Intranasal oxytocin is reportedly used by some midwives as a galactogogue. It has also been used as part of regimens used by adoptive mothers who wish to breastfeed.

A small study found no difference in symptoms between subcutaneous oxytocin 2.5 international units daily and placebo after 3 days of treatment for breast engorgement.

An early randomized, placebo-controlled trial used oxytocin nasal spray in the mothers of newborns, but lactation management fell far short of what is considered acceptable nowadays. The study found that the spray might be useful in decreasing breast engorgement slightly in the mothers of full-term infants, but no difference was found in the average infant weight loss between birth and day 4 in the oxytocin and placebo groups.

Two similarly designed trials studied oxytocin nasal spray in mothers of preterm newborns who were pumping milk for their infants. The first studied mothers of infants born before 38 weeks and used a total of 3 units of intranasal oxytocin (Syntocinon-Sandoz, 40 units/mL) before pumping each breast for 10 minutes four times daily. Among primiparous mothers, milk production during days 2 to 5 days postpartum was 1964 mL in those who used oxytocin and 510 mL in those who received placebo spray. Because of the large and statistically significant effect of oxytocin among primiparous women, the trial was stopped after only 8 primiparous mothers had been studied. No statistically significant difference was found between oxytocin and placebo among 4 multiparous women who were attempting to breastfeed for the first time. The paper did not report giving the mothers any instructions in lactation technique.

Fifty-one mothers who delivered an infant of less than 35 weeks gestation were studied. Twenty-seven mothers used 4 units of intranasal oxytocin (Syntocinon-Novartis, 40 units/mL), and 24 mothers received an identical placebo spray before pumping with a breast pump. All mothers were given instructions on using hand massage before pumping and advised pumping every 3 hours. No difference in milk production over the first 5 days postpartum was found between mothers who received oxytocin (median 667 mL) and placebo (median 530 mL), although women receiving oxytocin produced slightly more milk on day 2 of the study. Parity had no effect in this study.

Several factors might explain the differences in findings between the studies. Because of the great interpatient variability in milk production documented in the recent study and the small number of patients in the first study, the finding in the earlier study may have been due to chance. A 50% higher dose of oxytocin was used in the first study, which may have had a greater effect. Another plausible explanation is the good lactation support given to mothers in the recent larger study that seemed to be lacking in the early study.

Two case reports indicate that oxytocin nasal spray may facilitate letdown in tetraplegic women who have lost the neuronal connection between the nipple and the hypothalamus.

A woman diagnosed with panhypopituitarism became pregnant and wished to breastfeed. On the second day postpartum, she began using 2 IU of oxytocin (Grindex, Australia) by nasal spray before each breastfeeding session. Initially, the use of intranasal oxytocin before every session of breastfeeding facilitated milk ejection, particularly in the early weeks postpartum. After one month, there was no observable difference that could be attributed to oxytocin administration, and breastmilk continued to flow by hand expression without it. At that point he mother decided to discontinue oxytocin. However, the milk volume was not sufficient for exclusive breastfeeding, even with the use of domperidone, goats’ rue, torbangun, and fenugreek, so her baby received supplementary infant formula.

During labor. A study of mothers who received oxytocin during labor found that on the second day postpartum, oxytocin infusion decreased endogenous oxytocin levels dose-dependently. Epidural analgesia in combination with oxytocin infusion influenced endogenous oxytocin levels negatively. Oxytocin infusion also increased serum prolactin.

Logistic regression of data from 585 mothers who had epidural analgesia during labor found that mothers who had received exogenous oxytocin had a 3.3 times greater risk of delayed onset of lactation than women who did not.

An observational study of 20 primiparous women found that those who were exclusively breastfeeding at 3 months (63%) had received a lower dose of oxytocin during labor (mean total dosage 1363 milliunits) than those who were not exclusively breastfeeding (mean total dosage 3088 milliunits). This result was attributed to an inhibitory effect on neonatal sucking by the infant caused by oxytocin.

A small, nonrandomized cohort study found that the newborn infants whose mothers received synthetic oxytocin to induce or maintain labor had a decreased level of prefeeding organization one hour after birth.

A retrospective cohort study in Spain compared breastfeeding outcomes between mothers who received oxytocin during labor (n = 189) and mothers who did not, including those who delivered via elective Cesarean section (n = 127). Mothers who received oxytocin during the first and second stages of labor had a 45% increased risk of bottle feeding and a 129% increased risk of breastfeeding discontinuation by 3 months of age. Effects were most pronounced in women under 27 years of age.

A small prospective study in California compared women who received an epidural infusion of fentanyl and ropivacaine to mothers who did not receive an epidermal during labor. All mothers had normal vaginal deliveries, and their infants had 1 uninterrupted hour of skin-to-skin contact immediately postpartum. The study found inverse relationships between the amount of fentanyl and the amount of oxytocin received during labor and the time of the first suckling. Because women who received more fentanyl also tended to receive more oxytocin, the study could not clearly separate the effects of the two drugs.

A small prospective cohort study in Spain followed mothers by telephone postpartum to determine their breastfeeding status. Mothers who had received oxytocin during labor were breastfeeding at a similar rate as those who had not at 1, 3 and 6 months postpartum.

A nonblinded, nonrandomized study compared breastfeeding among the infants of mothers who received oxytocin during delivery (n = 70) and those who did not (n = 90) in two Iranian hospitals. Mothers were primiparous and infants were full term. Infant breastfeeding behavior was assessed to be either successful or unsuccessful within 2 hours of delivery. Infants whose mothers received oxytocin were judged to successfully breastfeed 48.6% compared to 82.2% among the infants of mothers who did not receive oxytocin. Use of opiate pain relievers in the two groups was not stated.

A retrospective cohort study compared breastfeeding results between women who did and did not receive oxytocin during labor. After correcting for confounding factors, the study found that exogenous oxytocin impaired breastfeeding during the first hour postpartum, but not at 3 months postpartum. High pregestational body mass index was the best predictor of an impaired third month's postpartum breastfeeding.

A retrospective case-control study conducted in two hospitals in central Iran compared breastfeeding behaviors in the first 2 hours postdelivery by infants of 4 groups of primiparous women with healthy, full-term singleton births who had vaginal deliveries. The groups were those who received no medications during labor, those who received oxytocin plus scopolamine, those who received oxytocin plus meperidine, and those who received oxytocin, scopolamine and meperidine. The infants in the no medication group performed better than those in all other groups, and the oxytocin plus scopolamine group performed better than the groups that had received meperidine.

A prospective cohort study in Spain found no relationship between oxytocin dose during labor or postpartum with the duration of breastfeeding. However, elective cesarean section without oxytocin resulted in the greatest risk of stopping exclusive breastfeeding.

An observational study in Sweden compared nursing behaviors of the infants of mothers who received intravenous oxytocin or intramuscular oxytocin with or without receiving epidural analgesia with sufentanil and bupivacaine. Infants of mothers who received oxytocin infusions alone during labor breastfed as well as those of mothers who had no interventions during labor. Mothers who received oxytocin plus epidural analgesia had reduced breastfeeding behaviors and more weight loss at 2 days postpartum than those who did not receive epidural analgesia. The mothers of infants who breastfed well had greater variability in serum oxytocin than those whose infants did not breastfeed well.

A study examined the effects of low, medium and high doses of intrapartum synthetic oxytocin administered to mothers who received no oxytocin. A dose-related decrease in several infant breastfeeding behaviors and the number of exclusive nursing bouts at 24, 48 and 72 hours was found, but there was no difference in the rate of exclusive breastfeeding at 3 months postpartum.

In a study of primiparous women with an uncomplicated pregnancy, women were given oxytocin 1 to 2 milliunits/min initially, with dosage increases of 1 to 2 milliunits/min every 30 minutes until effective contractions were achieved, up to a maximum of 20 milliunits/min. Some women received epidural analgesia with ropivacaine and fentanyl, some received oxytocin alone and other received neither. Breastfeeding outcomes in the three groups were compared at 3 days, 1 month and 4 months postpartum. The study found no relationship between this low-dose oxytocin use and breastfeeding success, but that epidermal analgesia reduced maternal salivary oxytocin levels, lowered milk supply at 3 days and 1 month postpartum, and decreased rates of breastfeeding at 4 months postpartum.

A case-control study in a hospital in Istanbul, Türkiye compared 44 women who received oxytocin for induction of labor to 44 women who did not. There was no significant difference between the mean scores of the Breastfeeding Self-Efficacy Scale and the LATCH scores between the two groups.

A multicenter study in Sweden compared breastfeeding outcomes of 1395 women who received oxytocin during labor. After adjusting for confounding variables (maternal age, early pregnancy BMI, epidural analgesia, and infant weight >4 kg), no difference was found in the breastfeeding rates at 1 week postpartum over the range of cumulative oxytocin dosages that the mothers received.

The sucking ability of 29 vaginally delivered infants whose mothers received oxytocin during delivery were compared to 35 infants whose mothers received no oxytocin. The average maternal oxytocin dose was 3.45 IU over an average of 354 minutes. The infants in the oxytocin group had fewer sucking bursts, longer times between bursts and more variability in sucking than those not exposed. At 1 month postpartum, infants exposed to oxytocin were less likely to be exclusively breastfed than those not exposed (17% vs 43%). The authors concluded that infant sucking ability was impaired for up to 48 hours after maternal oxytocin infusion during labor.

Maternal and neonatal salivary oxytocin levels were measured before and after breastfeeding at 24 to 48 h postpartum in women who did (n = 23) or did not (n = 26) receive oxytocin during labor. Neonatal sucking ability was assessed after 5 min of non-nutritive sucking, and breastfeeding practices were evaluated at 72 hours and 1 month postpartum. Intrapartum oxytocin did not significantly affect maternal oxytocin but was associated with reduced neonatal salivary oxytocin and weaker sucking patterns, suggesting that exogenous oxytocin during labor interferes with neonatal oxytocin regulation and early feeding.

A subanalysis of a large multicenter study (n = 2,130) of women who delivered between 34 weeks 0 days and 36 weeks 6 days found that there was no difference in breastfeeding rates among the infants of women who received labor induction and those who did not.